Zhong Guo Zheng Quan Bao·2026-01-07 15:19Group 1 - Kelong Pharmaceutical has seen a reduction in holdings by the China Europe Medical Health Mixed Fund managed by fund manager Ge Lan, from 42.60 million shares at the end of Q2 2025 to 38.20 million shares by the end of Q4 2025, indicating a decrease of 1.87 million shares [1] - The same fund had already begun reducing its stake in Kelong Pharmaceutical in Q3 2025, where the holdings decreased from 42.60 million shares to 40.06 million shares, a reduction of 2.53 million shares [1] - In contrast, the Industrial Bank of China Credit Suisse Frontier Medical Stock Fund managed by Zhao Bei increased its holdings in Kelong Pharmaceutical from 20.00 million shares at the end of Q3 2025 to 22.00 million shares by the end of Q4 2025 [1] Group 2 - Proya, another well-known consumer goods company, announced a share buyback on January 5, 2025, revealing that the Invesco Great Wall Emerging Growth Mixed Fund managed by Liu Yanchun reduced its holdings from 3.33 million shares at the end of Q3 2025 to 2.60 million shares by the end of December 30, 2025, a decrease of over 700,000 shares [2] - Additionally, the fund managed by Hu Xinwei, the Huatai-PineBridge Consumer Industry Mixed Fund, has exited the top ten circulating shareholders of Proya [2]